TOKYO: US tech giant OpenAI on Monday (Feb 3) unveiled a ChatGPT tool called "deep research" ahead of high-level meetings in Tokyo, as China's DeepSeek chatbot heats up competition in the AI field.

Objective To explore the risk factors of perioperative deep vein thrombosis (DVT) in patients with traumatic fracture after orthopaedic surgery and their potential diagnostic values in clinical.

After the Operator AI agent, OpenAI has added a new Deep Research AI agent for ChatGPT Pro users. It can go to the web and perform research for you independently. The agent takes 5 to 30 minutes to ...

Valve thrombosis can occur in mechanical prosthetic valves and is increasingly recognised in transcatheter and surgically implanted bioprosthetic valves. The risk of thrombosis of mechanical valves is ...

The Sensex ended the day at 75,366.17, plunging 824.49 points or 1.08%. (Image/Freepik) Foreign institutional investors (FIIs) continued to exit stocks on Monday with net sales of over Rs 5,000 ...

When investors take a deep look at the valuations they've been paying to chase the same 10 stocks, there could be a reckoning. First, we need to find out if the DeepSeek AI news is true.

“DeepSeek R1 is now available on Perplexity to support deep web research. There's a new Pro Search reasoning mode selector, along with OpenAI o1, with transparent chain of thought into model's ...

Of all the audacious tasks the new Trump administration and its congressional allies have taken on, perhaps the most intense and far-reaching are their efforts to go after the so-called deep state ...

Chinese AI chatbot DeepSeek has displaced OpenAI’s ChatGPT as the most downloaded app on the Apple App store and the market is panicking. Stocks for major AI connected companies like NVIDIA fell ...

Welcome to 9to5Neural. AI moves fast. We help you keep up. Last week we mentioned that American AI firms are seeing deep competition from DeepSeek R1 out of China. Today DeepSeek’s impact has ...

treated with mFOLFIRINOX. Comparison of hospital outcomes between pancreatic cancer patients with and without portal vein thrombosis.